Pfizer submits early data on boosters’ protection to FDA

Pfizer Inc. and BioNTech SE submitted early-stage data to U.S. regulators showing that a third dose of their Covid-19 vaccine led to higher levels of protective antibodies when given eight to nine months after the initial regimen.

The companies expect data from a larger final-stage trial evaluating the effects of the third booster dose shortly, according to a statement Monday, which will be submitted to the U.S. Food and Drug Administration, the European Medicines Agency and other regulatory authorities. Shares of New York-based Pfizer was little changed at 11:51 a.m. on Monday, while the German BioNTech’s American depository receipts were down 10%